How to treat MDS without stem cell transplantation

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Allogeneic hematopoietic cell transplantation (HCT) is the only curative option for myelodysplastic syndromes (MDS).
• HCT is unsuitable for a majority of MDS patients due to age and comorbidities.
• Current treatments for higher-risk MDS focus on preventing leukemic transformation, while lower-risk MDS management prioritizes quality of life.

Purpose of the Study:

• To review current treatment strategies for myelodysplastic syndromes (MDS).
• To highlight the limitations of allogeneic HCT in the MDS patient population.
• To discuss alternative therapeutic approaches for different risk groups within MDS.

Main Methods:

• Literature review of existing studies on MDS treatments.
• Analysis of treatment outcomes based on patient risk stratification.
• Synthesis of current clinical practices for managing MDS.

Main Results:

• Allogeneic HCT is effective but limited to a small subset of younger, healthier MDS patients.
• Higher-risk MDS patients require interventions to prevent progression to acute myeloid leukemia.
• Lower-risk MDS patients benefit from supportive care aimed at improving quality of life.

Conclusions:

• Treatment decisions for myelodysplastic syndromes must be individualized based on risk stratification and patient factors.
• Development of safer and more effective alternative therapies for MDS is crucial.
• Optimizing quality of life remains a key goal for lower-risk MDS management.